Is Dose-Dense Therapy Effective Against DLBCL in the Era of Rituximab?Cancer NetworkThe authors asked whether there is still debate surrounding dose intensity since the introduction of the monoclonal antibody rituximab (Rituxan [R]), which has improved…
Viropro, Inc. to Unlock Value from its Biosimilars PortfolioGenetic Engineering News (press release)It is from this portfolio that Viropro signed a Letter of Agreement with Spectrum Pharmaceuticals, Inc. for Rituximab, and is in active discussions with…
Viropro, Inc. to Unlock Value from its Biosimilars PortfolioMarketWatch (press release)The starting line-up and portfolio consists of sophisticated biosimilar molecules such as Ranibizumab (biosimilar of Lucentis(R)), Trastuzumab (-Herceptin(R)), Ritux…
Rituximab Works for Some ChildrendailyRxRecent studies have identified rituximab (sold as Rituxan) as a possible treatment for a childhood kidney disorder. The drug may allow children to stop taking the standard drug treatment, which can be toxic. Ritu…
Cell Therapeutics' lymphoma drug, Pixuvri gets EU conditional marketing approvalpharmabiz.comThe EMA's Committee for Medicinal Products for Human Use (CHMP) has accepted PIX306, CTI's ongoing randomized controlled phase 3 clinical trial, wh…
Rituximab Little Use in Resistant Idiopathic Nephrotic SyndromeDoctors LoungeThe anti-CD20 monoclonal antibody, rituximab, added to prednisone and calcineurin inhibitors, does not provide any additional benefit in terms of reduced proteinuria in the tr…
Personal struggle led to fundraising successWoodstock Sentinel ReviewEvery 14 to 21 months Ropp received Rituximab, a mild form of chemotherapy treatments that helped her go into a remission state. “They (the treatments) helped to get me off the ster…
Rituximab does not appear to benefit children with INSNews-Medical.netThe drug rituximab, an antibody that targets the immune system and is often used to treat immune disorders such as lymphoma and arthritis, has recently emerged as a potential treatme…
Clinical Oncology NewsNew Antibody Promising for Relapsed LymphomaClinical Oncology NewsSan Diego—In the first head-to-head comparison, obinutuzumab (GA101, Genentech) appeared to be more active than rituximab in relapsed CD20-positive indolent B-cel…
Immune drug doesn't help kids with hard-to-treat kidney disorderEurekAlert (press release)Children with a particular kidney immune disorder that is unresponsive to standard treatments do not benefit from the immune drug rituximab. Additional studie…